Roma, 4 Ottobre 2019 Relatore: Francesca Poggio
U.O. Oncologia Medica 2
IRCCS Ospedale Policlinico S.Martino , Genova
2019 CARCINOMA MAMMARIO: I TRAGUARDI RAGGIUNTI E LE NUOVE SFIDE
Lo studio GIM4
15
0
0
Testo completo
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
Documenti correlati
When residual lymph node disease is present, the size of the largest focus of residual tumor is used to determine the ypN classification, and treatment-associated fibrosis is
pazienti con rischio clinico e genomico discordante (stime imprecise, CI ampli) Lo studio Mindact confronta 2 sistemi di classificazione SENZA integrarli (score. multivariati
• Riscontro, mediante mammografia, di nodulo di circa 15mm alla mammella sinistra.. Ascella
Historically proposed to enable breast-conserving surgery in stage II-III, in particular for triple negative and HER2-positive EBC...
• Ci sono tante buone ragioni per i chirurghi per adottare la CNA più frequentemente. • Algoritmi per diminuire l’incidenza di FN dopo CNA
• Exploratory endpoints were: the percentage change in total lumbar spine, total hip and femoral neck BMD from baseline to Months 12 and 24 (at preselected sites); the
PFS2=progression-free survival 2, ORR=objective response rate, HRQoL=health-related quality of life, FSI=first subject in, RECiST= Response Evaluation Criteria in Solid
- DFS benefit with ovarian suppression only in higher risk patients receiving chemotherapy.. - Ovarian suppression + AI better, especially in pts
